Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04665947 · ClinicalTrials.gov registry record · Early Phase 1
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
A Early Phase 1 study of Metastatic Pancreatic Cancer and Locally Advanced Pancreatic Adenocarcinoma, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04665947: Recruiting Early Phase 1 study of Metastatic Pancreatic Cancer and Locally Advanced Pancreatic Adenocarcinoma, sponsored by University of California, Davis.
NCT04665947 is a Early Phase 1 study of Metastatic Pancreatic Cancer and Locally Advanced Pancreatic Adenocarcinoma that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 30 participants, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04665947, a Early Phase 1 study of Metastatic Pancreatic Cancer and Locally Advanced Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I, first-in-human study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or metastatic pancreatic adenocarcinoma (PDAC).
Primary Outcome
Assessment of \[68Ga\]Ga DOTA-5G PET/CT imaging to detect lesions in patients with locally advanced or metastatic pancreatic cancer
Conditions Studied
Interventions
- DRUG [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
Study Locations (1)
California
- University of California Davis - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-12-18 |
| Est. Completion | 2026-06 |
| Phase | Early Phase 1 |
What NCT04665947 shows while recruiting
NCT04665947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Metastatic Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. is the first listed.
NCT04665947 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04665947 about?
NCT04665947 is a clinical study titled "First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer". This is a Phase I, first-in-human study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or metastatic pancreatic adenocarcinoma (PDAC).
What is the current status of trial NCT04665947?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2020-12-18. Estimated completion is 2026-06.
What conditions does trial NCT04665947 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT04665947?
The interventions under investigation include: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. (DRUG).
Who is sponsoring clinical trial NCT04665947?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04665947 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04665947's enrollment target sits among peer trials
30 17th of 32 higher than 10 of 32 other Metastatic Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
RECRUITING · Phase 1
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI